Cipla recalls 4,800 bottles of anti-HIV tablets from US

Drug major Cipla is recalling 4,800 bottles of Nevirapine extended release tablets used for the treatment of human immunodeficiency virus (HIV) from the American market, according to a report by the US health regulator.

As per the latest Enforcement Report by the United States Food and Drug Administration (USFDA), the reason for the recall of the bottles is ‘failed dissolution specifications’.

Nevirapine extended release tablets, 400 mg in the 30-count bottle have been manufactured by Cipla at its Goa facility for Cipla USA Inc, it added.

The US health regulator has not yet classified the voluntary recall by the company, the report said.

  • Related Posts

    Meiji Seika to push new vaccine with SII in India

    TOKYO: Meiji Seika Pharma-owned Medreich Pharma is eyeing inorganic growth and more generics supply from India, while the parent has tied up with Serum Institute of India (SII) to launch…

    DGFT automates EO extension process to ease compliance for pharma exporters

    Mumbai: The Directorate General of Foreign Trade (DGFT) has introduced an automated facility for granting Export Obligation (EO) extensions in Advance Authorisation and Export Promotion Capital Goods (EPCG) Authorisation cases…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Meiji Seika to push new vaccine with SII in India

    Meiji Seika to push new vaccine with SII in India

    DGFT automates EO extension process to ease compliance for pharma exporters

    DGFT automates EO extension process to ease compliance for pharma exporters

    Udan vs Udaan: Delhi court restrains pharmaceutical firm from using ‘Udaan’ mark

    Udan vs Udaan: Delhi court restrains pharmaceutical firm from using ‘Udaan’ mark

    Three newborns die in fire at government hospital in Amravati, Maharashtra

    Three newborns die in fire at government hospital in Amravati, Maharashtra

    Maharashtra FDA to prioritise process audits for revised Schedule M compliance: FDA Commissioner

    Maharashtra FDA to prioritise process audits for revised Schedule M compliance: FDA Commissioner

    Centre bans fixed-dose combination for Common Cold in children below four

    Centre bans fixed-dose combination for Common Cold in children below four